Decera Clinical Education Oncology Podcast
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer
Listen in to learn from Cristina Saura Manich, MD, PhD and Giampaolo Bianchini, MD about practical approaches to PI3K pathway testing, PI3K/AKT-targeted treatment options, and endocrine-based sequencing in metastatic breast cancer.
Presenters:
Cristina Saura Manich, MD, PhD
Head, Breast Cancer Unit
Medical Oncology Service
Vall d'Hebron University Hospital
Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Giampaolo Bianchini, MD
Associate Professor, Universita Vita-Salute San Raffaele
Head, Breast Cancer Group, Department of Medical Oncology
Head, Clinical Translational and Immunotherapy Research<...
Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider
Link to claim CME credit:
https://bit.ly/4uRr3ir
In this episode, Elizabeth Krueger, NP, and Sam Vafadar, DHSc, PA-C, discuss how they optimize first-line EGFR-targeted therapy for patients with EGFR-mutated NSCLC, including:
First-line treatment options available for EGFR-mutated NSCLC and the clinical trials that resulted in their approval Adverse event identification and management Generalized strategies to support patient adherence to TKIsGet access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify
Presenters:
Elizabeth Krueger, NP
Advancing the Early Detection of Lung Cancer: Expanding Screening Access, Eligibility, and Awareness
In this episode, Dr Abbie Begnaud discusses the importance of lung cancer screening and evolving strategies to improve early detection among high-risk populations, including:
Low-dose CT screening, which reduces lung cancer mortality by detecting cancers at earlier, more treatable stages Updated screening guidelines that have expanded eligibility Key challenges that impact screening participation, including awareness, access, and broader risk assessmentGet access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenter:
Abbie Begnaud, MD, FCCP
Associate Professor of...
HNSCC: Current and Emerging Therapeutic Strategies
In this episode, Aarti Bhatia, MD, MPH, and Deborah J. Wong, MD, PhD, discuss the rapidly evolving treatment landscape for recurrent, metastatic, and locally advanced head and neck squamous cell carcinoma (HNSCC), including the growing role of immune checkpoint inhibitors, perioperative treatment strategies, EGFR-targeted bispecific antibodies, antibody–drug conjugates, HPV-targeted vaccines, and novel radiosensitizers. The discussion also explores emerging phase III clinical trials, treatment sequencing considerations, and future precision oncology approaches for HPV-positive and HPV-negative patients with head and neck cancer.
Presenters:
Aarti Bhatia, MD, MPH
Associate Professor of Medicine (Medical Oncology)
Clinical Rese...
Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies
In this episode, hear Doris K. Hansen, MD, discuss the management of relapsed/refractory multiple myeloma with bispecific antibodies including:
Practical differences among approved bispecific antibodies Toxicity profiles of approved bispecific antibodies When to refer patients for evaluation for immunotherapies Considerations for sequencing bispecific antibodies in the relapsed/refractory setting New findings with combination regimens with bispecific antibodiesProgram faculty:
Doris K. Hansen, MD
Assistant Member, Blood and Marrow Transplant and Cellular Immunotherapy
H. Lee Moffitt Cancer Center & Research Institute
Assistant Professor
University of South Florida Morsani College of Medicine
Tampa...
Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma
In this episode, Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, discuss various strategies to optimize the use of bispecific antibodies in their practices for the treatment of R/R MM through patient monitoring, dosing in outpatient settings, and using tocilizumab and IVIG, among other management strategies.
Presenters:
Muhamed Baljevic, MD, FACP
Associate Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Director, Multiple Myeloma Program
Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP)
Co-Chair, Scientific Review Committee, VICC
Disease Team Lead, Plasma Cell Dyscrasias and Lymphomas
Vanderbilt-Ingram Cancer Ce...
Thrombotic Events and ET/PV: What You Should Know
In this episode, hear Anthony Hunter, MD and Douglas Tremblay, MD discuss the various presentations of thrombotic events in patients with PV or ET including how thrombotic events may lead to diagnosis:
PV and ET increase the risk of both arterial and venous thrombotic events Unusual thrombotic events Thrombosis as initial presentation for MPN Case presentations Brief overview of thrombosis managementProgram faculty:
Anthony M. Hunter, MD
Associate Professor, Department of Hematology and Medical Oncology
Leader, Myeloproliferative Neoplasm Program
Medical Director, Rollins Immediate Care Center
Winship Cancer Institute of Emory University, Leu...
Global Experts Discuss Current and Emerging Treatments for ET and PV
In this podcast episode, Ciro Rinaldi MD, PhD, and Alessandro M. Vannucchi, MD, discuss contemporary management of essential thrombocythemia (ET) and polycythemia vera (PV), as well as novel investigational approaches, including the following:
Overview of current treatment paradigms for PV and ET Importance of shared decision-making and patient communication in determining treatment Current therapeutic areas of need in ET and PV Emerging investigational therapeuticsPresenters:
Ciro Rinaldi MD, PhD
Chief Medical Officer, United Lincolnshire Teaching Hospital
Honorary Professor of Haematology, University of Lincoln
Honorary Professor De Montfort University Dubai
Consultant Haematologist
Li...
Global Experts Discuss Diagnostic Considerations in ET and PV
In this podcast episode, Ciro Rinaldi, MD, PhD, and Alessandro M. Vannucchi, MD, as they discuss contemporary topics in diagnosing essential thrombocythemia (ET) and polycythemia vera (PV), including:
Overview of diagnostic criteria for PV and ET Importance of bone marrow biopsy Degree of suspicion of PV/ET in patients presenting with thrombotic events Pearls of wisdom in diagnosisPresenters:
Ciro Rinaldi, MD, PhD
Chief Medical Officer, United Lincolnshire Teaching Hospital
Honorary Professor of Haematology, University of Lincoln
Honorary Professor De Montfort University Dubai
Consultant Haematologist
Lincoln, United Kingdom
Ale...
Experts Discuss Novel Approaches to First-line Therapy for HER2-Positive Metastatic Breast Cancer
In this podcast episode, Erika Hamilton, MD, FASCO, and Ian Krop, MD, PhD, discuss recent developments in the field of first-line therapy and maintenance treatment for patients with HER2-positive metastatic breast cancer, including the following:
Trastuzumab deruxtecan plus pertuzumab as first-line therapy based on data from DESTINY-Breast09 Adding palbociclib to HP and ET as maintenance therapy for HR-positive/HER2-positive MBC, based on data from PATINA Adding tucatinib to HP as maintenance therapy for HER2-positive MBC, based on data from HER2CLIMB-05Presenters:
Erika Hamilton, MD, FASCO
Chief Development Officer, Late Phase
...
Patient Voices: Caring for the Whole Patient and Personalizing Treatment of Early Breast Cancer to Achieve Equitable Outcomes
A patient advocate/cancer survivor and a healthcare professional discuss key topics including early breast cancer diagnosis, role of self-agency in pursuing optimal cancer care, encouraging trial participation with patient testimonials, and other considerations for the patient care journey such as appropriate screening, follow-up encounters for questions, guideline-based treatments, and side effect management.
Participants
Kristen D. Whitaker, MD, MS
Breast Medical Oncologist
Medstar Georgetown Center Institute at Washington Hospital Center
Assistant Professor of Medicine
Georgetown University School of Medicine
Washington, DC
Asha Miller
Founder, Asha Miller Creative
Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities
Podcast with global experts discussing the role of AKT and PI3K inhibitors in patients with resistance to endocrine therapy in the adjuvant or metastatic disease settings following current guidelines, indications, and best clinical practices.
Presenters:
Nadia Harbeck, MD
Breast Cancer Director
Department of OB&GYN and Comprehensive Cancer Center Munich
LMU University Hospital
Munich, Germany
Francois-Clement Bidard, MD, PhD
Breast Medical Oncology
Institut Curie & University of Versailles
Paris, France
Link to full program:
https://bit.ly/4cFd0Xj
Get access...
Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer
In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss patient-centered management of CDK4/6 inhibitor therapy in HR-positive/HER2-negative breast cancer, with a focus on how oncology pharmacists and the multidisciplinary care team can support patients through treatment, including:
Practical strategies for monitoring and managing key adverse events associated with abemaciclib, ribociclib, and palbociclib, such as diarrhea, neutropenia, hepatotoxicity, and QT prolongation How dose interruptions and dose reductions can help improve tolerability while maintaining clinical benefit Real-world approaches to patient education, toxicity counseling, and communication that can improve adherence and persistence with oral CDK4/6...TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions
In this episode, Dr Matthew Gubens and Dr Helena Yu discuss the evolving role of TROP2-directed therapies in non-small-cell lung cancer, with a focus on how antibody–drug conjugates (ADCs) fit into current treatment strategies, including
The mechanism of action and clinical trial outcomes of TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan Use of these therapies in EGFR-mutant disease and how they fit into a changing treatment landscape Practical advice on associated adverse events and additional considerations, A look at future directions on the horizon, such as first-line studies and predictive biomarkersGet access to...
Emerging Therapies for Patients With HER2+ Gastroesophageal Adenocarcinoma and Biliary Tract Cancer
In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the individualized care of patients with HER2-positive gastroesophageal adenocarcinoma and biliary tract cancer, including:
A brief overview of BTC and GEA Notable findings from a recent survey of healthcare professionals on BTC and GEA Case studies on recommended management of patients with BTC or GEA Emerging datasets of HER2-directed therapies in BTC and GEA affecting clinical practice Challenges faced by healthcare professionals in the management of patients with BTC and/or GEA Key ongoing trials of HER2-directed th...Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC
In this podcast episode, Aditya Bardia, MD, MPH, FASCO, and Ruta Rao, MD, discuss ADCs for HER2-negative/ultralow/low metastatic breast cancer, including:
Classifying HER2 expression in MBC today (HER2 negative/ultralow/low/positive) and why this is important ADCs for HER2-negative/ultralow/low MBC Patient communication: best practices in discussing treatment goals and potential AEsPresenters:
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine
University of California
Los Angeles, California
Ruta Rao, MD
Medical Director, Rush University Cancer Center
Professor of M...
Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Colorectal Cancer
Advanced practice providers discuss biomarker testing in patients with colorectal cancer. Listen in to learn from Ann Marie Siney, RN, MSN, ANP-BC, and Kathleen Boyle, DScPAS, PA-C, about familial cancer syndromes associated with colorectal cancer and key biomarker testing often used in patients with colorectal cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker for all patients.
Presenters:
Ann Marie Siney, RN, MSN, ANP-BC
Division of Hematology/Oncology
UCLA Health
Santa Monica, California
Kathleen Boyle, DScPAS...
Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Prostate Cancer
Listen to this audio podcast covering biomarker testing in patients with prostate cancer. Learn from Sara Traverso, MMS, PA-C, and Brenda Martone, MSN, ANP-BC, AOCNP, about when to conduct germline and somatic genetic testing in patients with prostate cancer, discussing testing with patients and their caregivers, recognizing actionable biomarkers, and improving APP confidence in the application of biomarker testing results to practice.
Presenters:
Sara Traverso, MMS, PA-C
Physician Assistant
Northwestern Medicine
Robert H. Lurie Comprehensive Cancer Center
Genitourinary Oncology
Chicago, Illinois
Brenda Martone, MSN, ANP-BC, AOCNP
Nurse P...
Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026
In this episode, Sam S. Chang, MD, MBA, and Matthew D. Galsky, MD, discuss the rapidly evolving treatment landscape in bladder cancer, highlighting new therapeutic options, emerging clinical trial data, including the latest results presented at ASCO GU 2026, and the growing role of biomarkers and multidisciplinary care, including:
New treatment options for BCG-unresponsive non–muscle-invasive bladder cancer Intravesical therapies such as nadofaragene and N-803 The role of ctDNA in measurable residual disease detectionPresenters:
Sam S. Chang, MD, MBA
Patricia and Rodes Hart Chair of Urologic Surgery
Chief Surgical Officer
Vanderbilt Ingram Ca...
Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization
In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making.
Presenters:
Rodney Hunter, PharmD, BCOP
Director of Clinical Services
Memorial Hermann Texas Medical Center
Clinical Pharmacy Specialist
University of Texas Health Memorial Hermann Cancer Center
Professor
Texas Southern University College of Pharmacy and Health Sciences
Clinical Adjunct Professor
McGovern Medical School
H...
From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL
In this episode, Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discuss how recently presented data from ASH 2025 are shaping real-world treatment decisions for patients with relapsed/refractory chronic lymphocytic leukemia, including:
How covalent and noncovalent BTK inhibitors are currently used in the United States, Brazil, and Europe Practical sequencing decisions after disease progression Emerging BTK degradersas a promising option for heavily pretreated patientsGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
M...
2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast
Listen to learn from Sara M. Tolaney, MD, MPH, and Virginia Kaklamani, MD, DSc,
about new clinical trial data and updates informing the care of patients with early breast cancer and locally advanced/metastatic breast cancer that were presented at the 2025 San Antonio Breast Cancer Symposium.
Presenters:
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Virginia Kaklamani, MD, DSc
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A...
Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions
In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including:
Clinical outcomes and limitations of first-generation KRAS G12C inhibitors Key unmet needs, including primary and acquired resistance Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapyPresenters:
Luis Paz-Ares, MD, PhD
Head of Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor, Universidad Complutense de Madrid
Madrid, Spain
Christine Bestvina, MD
Associate Professor
University of Chicago Medicine
Division...
Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies
In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including:
CD19-directed CAR T-cell therapies Next-generation CD19 bispecific antibodies The evolving role of allogeneic transplantPresenters:
Ibrahim Aldoss, MD
Associate Professor
Division of Leukemia
Department of Hematology/HCT
City of Hope National Medical Center
Duarte, California
Bijal Shah, MD, MS
Senior Member, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida
Link to...
Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer
In this podcast episode, Nilofer Azad, MD, FASCO, and Zev A. Wainberg, MD, discuss novel RAS-targeted therapies for pancreatic cancer, including the following:
Optimal KRAS mutation testing Emerging multiselective RAS inhibitors Combination strategiesPresenters:
Nilofer Azad, MD, FASCO
Professor of Oncology
Associate Director of Clinical Research
Sidney Kimmel Cancer Center at Johns Hopkins University
Co-Leader, Developmental Therapeutics Clinical Trials Group
Baltimore, Maryland
Zev A. Wainberg, MD
Professor of Medicine and Surgery
Co-Director, GI Oncology Program
UCLA School of Medicine
Los Angeles, California
Co...
Advanced Practice Professionals Discuss Biomarker Testing in Patients With Solid Tumors: Lung Cancer
Advanced practice providers discuss biomarker testing in patients with lung cancer. Listen in to learn from Beth Sandy, MSN, CRNP,FAPO, and Denise Rouse, MS, PA-C, about key biomarker testing in patients with lung cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker testing in patients with lung cancer.
Presenters:
Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Denise Rouse, MS, PA-C
Physician Assistant
Th...
Individualized Hemophilia Care With Hemostatic Rebalancing Therapies
In this podcast episode, experts Angela Weyand and Guy Young discuss their experience using hemostatic rebalancing agents for prophylaxis in patients diagnosed with hemophilia. Three rebalancing agents have now been approved, including concizumab, fitusiran, and marstacimab. These new rebalancing agents target the body's natural anticoagulants and provide individualized, convenient options for patients older than 12 years of age.This podcast explores similarities and differences between the rebalancing agents, such as dosing, necessary lab testing, and safety profiles, that are important to discuss with patients and their caregivers.
Presenters:
Angela Weyand, MD
Associate Professor, Pediatric Hematology On...
Experts Offer Guidance on Shared Decision-making in the Management of Patients With PV/ET
In this episode, hear Joan How, MD and Pankit Vachhani, MD share their insights on the importance of shared decision-making (SDM) for patients with polycythemia vera (PV) or essential thrombocythemia (ET) including:
Personal insights and examples of the process of SDM with patients with PV or ETHow nuances of managing PV/ET influence SDMIndividualizing the process of SDMBarriers to effective SDMEducational resources for patients with PV, ET, or MPNsWorking with a team to incorporate SDM into clinical practiceProgram faculty:
Joan How, MD
Scientific and Medical Consultant
Clinical Chief of Hematology
Brigham a...
Experts Discuss CELMoD Agents for Treating Multiple Myeloma
In this podcast episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including:
Combination strategiesAdverse event managementWhere CELMoD agents may best fit within current and future treatment strategiesPresenters:
Jesus Berdeja, MD
Director of Multiple Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee
Amrita Krishnan, MD, FACP
Director, Judy and Bernard Center for Myeloma, City of Hope
Nason Hollingsworth Family Chair Myeloma
Executive Director, Hematology, City of Hope Ora...
PulseCast: Highlights in MDS/MPNs From the 2025 ASH Annual Meeting
In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including:
Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MFAbstract 1024: Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential ThrombocythemiaAbstract 484: Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MFAbstract 235: VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Tre...Expert Highlights From the 2025 World Conference on Lung Cancer
In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials).
Presenters:
John Heymach, MD, PhD
Chair and Professor
Department of Thoracic/Head and Neck Medical Oncology
Ruth Legett Jones Distinguished Chair
MD Anderson Cancer Center
Houston, Texas
Solange Peters, MD, PhD
Professor and Director of Medical Oncology
Department of Oncology
University Hospital of L...
PulseCast: Highlights in Multiple Myeloma From the 2025 ASH Annual Meeting
In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following:
MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM RedirecTT-1: Updated efficacy and safety of talquetamab + teclistamab in R/R MM and extramedullary diseaseCARTITUDE-4: Results following treatment with cilta-cel in patients with standard-risk cytogeneticsSTEM: Preliminary safety and efficacy data from the phase II study of cevostamab consolidation following BCMA-directed CAR T-cell therapyCAMMA1: Biomarker analyses f...PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting
In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including:
CLL17: randomized phase III trial of continuous ibrutinib vs fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib for untreatedCLL BRUIN CLL-313: randomized phase III trial of pirtobrutinib vs BR for previously untreated patients with CLLBRUIN CLL-314: pirtobrutinib vs ibrutinib in treatment-naive and BTKi-naive R/R CLL/SLL EPCORE-FL-1: randomized phase III...PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting
In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including:
LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatmentAbstract 844: Secondary analysis results from VAYHIT3, a phase II study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least 2 lines of therapyAbstract 5: Deciphering the dilemma: intravenous (IV) iron u...PulseCast: Highlights in Leukemias From the 2025 ASH Annual Meeting
In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:
Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AMLAbstract 47: Phase I/II SAVE trial of revumenib plus decitabine/cedazuridine and venetoclax in the cohort of patients with newly diagnosed AMLAbstract 766: Phase Ib KOMET-007 trial of ziftomenib in combination with venetoclax and azacitidine in newly...TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?
In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:
TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan TROP2 ADCS for patients with EGFR-mutated NSCLCTIGIT-targeting agents: domvanalimab, rilvegostomigPresenters:
Benjamin Levy, MD, FASCO
Associate Professor
Johns Hopkins School of Medicine
Clinical Director
Johns Hopkins Kimmel Cancer Center, National Capitol Region (NCR)
Washington, DC
Alex Spira, MD, PhD, FASCO
Director Clinical Research
Virginia Cancer Specialists
CEO N...
A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer
In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including:
Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selectionThe recently approved targeted therapy combination regimen of avutometinib and defactinib for KRAS-mutant LGSOC (RAMP 201)Promising future directions for patients with LGSOC based on ongoing studies such as RAMP 301 and CHAMELEONPresenters:
Rachel Grisham, MD
Section Head of Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Director G...
CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach
In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including:
Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancerResults of the phase II REJOICE-Ovarian01 study in patients with platinum-resistant diseaseHow R-DXd may be incorporated into the treatment paradigmOther investigational CDH6-targeting ADCs: CUSP06, SIM0505Presenters:
Kathleen N. Moore, MD, MS, FASCO
Deputy Director and Cancer Therapeutics Co-Lead
Stephenson Cancer Center at the University of Oklahoma
Professor
Department of OB...
Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care
In this podcast, Dr David Miller, MD, PhD, FAAD and Dr Vishal Patel, MD discuss the evolving treatment landscape and immunotherapeutic strategies for cutaneous squamous cell carcinoma (cSCC) based on key data from pivotal studies that are reshaping standards of care, including:
Trials of neoadjuvant immunotherapies demonstrating remarkable response rates with PD-(L)1 inhibitors such as cemiplimab, pembrolizumab, atezolizumab, and nivolumab with or without ipilimumabOngoing investigational efforts, including the phase III CLEAR CSCC study of intralesional immunotherapy and radiation-immunotherapy sequencingPresenters:
David M. Miller, MD, PhD, FAAD
Director, Center for Merkel Cell Carcinoma
...
Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management
In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes and quality of life. The conversation blends clinical insights with practical considerations for therapy selection and patient care, including:
The pathogenesis of PNH and the role of complement activationLandmark therapies such as eculizumab and ravulizumabAdvances in proximal inhibitors (eg, pegcetacoplan, iptacopan, danicopan)Quality-of-life considerations, treatment personalization, and emerging therapiesPr...
